250 related articles for article (PubMed ID: 7692921)
21. Improved priming for mobilization of and optimal timing for harvest of peripheral blood stem cells.
Knudsen LM; Gaarsdal E; Jensen L; Nielsen KJ; Nikolaisen K; Johnsen HE
J Hematother; 1996 Aug; 5(4):399-406. PubMed ID: 8877715
[TBL] [Abstract][Full Text] [Related]
22. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R
Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898
[TBL] [Abstract][Full Text] [Related]
23. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients.
Schmitz N; Linch DC; Dreger P; Goldstone AH; Boogaerts MA; Ferrant A; Demuynck HM; Link H; Zander A; Barge A
Lancet; 1996 Feb; 347(8998):353-7. PubMed ID: 8598700
[TBL] [Abstract][Full Text] [Related]
24. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy.
Elias AD; Ayash L; Tepler I; Wheeler C; Schwartz G; Mazanet R; Schnipper L; Frei E; Antman K
J Hematother; 1993; 2(3):377-82. PubMed ID: 7522891
[TBL] [Abstract][Full Text] [Related]
25. Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.
Josting A; Reiser M; Wickramanayake PD; Rueffer U; Draube A; Söhngen D; Tesch H; Wolf J; Diehl V; Engert A
Leuk Lymphoma; 2000 Mar; 37(1-2):115-23. PubMed ID: 10721775
[TBL] [Abstract][Full Text] [Related]
26. Mobilization of peripheral blood progenitor cells following CHOP treatment combined with delayed granulocyte colony-stimulating factor administration in patients with non-Hodgkin's lymphoma.
Takano H; Sawada K; Sato N; Natoya A; Tarumi T; Hirayama S; Koizumi K; Takahashi TA; Sekiguchi S; Koike T
Leuk Lymphoma; 1996 May; 21(5-6):473-8. PubMed ID: 9172813
[TBL] [Abstract][Full Text] [Related]
27. Timing of platelet recovery is associated with adequacy of leukapheresis product yield after cyclophosphamide and G-CSF in patients with lymphoma.
Zimmerman TM; Michelson GC; Mick R; Grinblatt DL; Williams SF
J Clin Apher; 1999; 14(1):31-4. PubMed ID: 10355661
[TBL] [Abstract][Full Text] [Related]
28. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF.
Hohaus S; Goldschmidt H; Ehrhardt R; Haas R
Exp Hematol; 1993 Apr; 21(4):508-14. PubMed ID: 7681782
[TBL] [Abstract][Full Text] [Related]
29. Development of a simplified single-apheresis approach for peripheral-blood progenitor-cell transplantation in previously treated patients with lymphoma.
Jones HM; Jones SA; Watts MJ; Khwaja A; Mills W; Fielding A; Goldstone AH; Linch DC
J Clin Oncol; 1994 Aug; 12(8):1693-702. PubMed ID: 7518861
[TBL] [Abstract][Full Text] [Related]
30. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
Weaver CH; Schwartzberg L; Li W; Hazelton B; West W
Bone Marrow Transplant; 1996 May; 17(5):715-21. PubMed ID: 8733687
[TBL] [Abstract][Full Text] [Related]
31. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
[TBL] [Abstract][Full Text] [Related]
32. Kinetics of peripheral blood mononuclear cell mobilization with chemotherapy and/or granulocyte-colony-stimulating factor: implications for yield of hematopoietic progenitor cell collections.
Webb IJ; Eickhoff CE; Elias AD; Ayash LJ; Wheeler CA; Schwartz GN; Demetri GD; Anderson KC
Transfusion; 1996 Feb; 36(2):160-7. PubMed ID: 8614968
[TBL] [Abstract][Full Text] [Related]
33. Autologous peripheral blood stem cell transplantation after high dose therapy in patients with advanced lymphomas.
Brice P; Marolleau JP; Dombret H; Lepage E; Baruchel A; Adam M; Miclea JM; Sitthy X; Gisselbrecht C
Bone Marrow Transplant; 1992 May; 9(5):337-42. PubMed ID: 1352162
[TBL] [Abstract][Full Text] [Related]
34. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
[TBL] [Abstract][Full Text] [Related]
35. Early total white blood cell recovery is a predictor of low number of apheresis and good CD34(+) cell yield.
Marques JF; Vigorito AC; Aranha FJ; Lorand-Metze I; Miranda EC; Lima Filho EC; Valbonesi M; Santini G; De Souza CA
Transfus Sci; 2000 Oct; 23(2):91-100. PubMed ID: 11035269
[TBL] [Abstract][Full Text] [Related]
36. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
Moskowitz CH; Glassman JR; Wuest D; Maslak P; Reich L; Gucciardo A; Coady-Lyons N; Zelenetz AD; Nimer SD
Clin Cancer Res; 1998 Feb; 4(2):311-6. PubMed ID: 9516916
[TBL] [Abstract][Full Text] [Related]
37. Feasibility of ESHAP + G-CSF as peripheral blood hematopoietic progenitor cell mobilisation regimen in resistant and relapsed lymphoma: a single-center study of 22 patients.
Petit J; Boqué C; Cancelas JA; Sarrà J; Muñoz J; Garcia J; Grañena A
Leuk Lymphoma; 1999 Jun; 34(1-2):119-27. PubMed ID: 10350339
[TBL] [Abstract][Full Text] [Related]
38. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).
Josting A; Kàtay I; Rueffer U; Winter S; Tesch H; Engert A; Diehl V; Wickramanayake PD
Ann Oncol; 1998 Mar; 9(3):289-95. PubMed ID: 9602263
[TBL] [Abstract][Full Text] [Related]
39. Correlation between granulocyte/macrophage-colony-forming units and CD34+ cells in apheresis products from patients treated with different chemotherapy regimens and granulocyte-colony-stimulating factor to mobilize peripheral blood progenitor cells.
Vogel W; Kunert C; Blumenstengel K; Fricke HJ; Kath R; Sayer HG; Höffken K
J Cancer Res Clin Oncol; 1998; 124(6):341-5. PubMed ID: 9692843
[TBL] [Abstract][Full Text] [Related]
40. Circulating stem cell collection in lymphoma and myeloma after mobilization with cyclophosphamide and granulocyte colony-stimulating factor for autologous transplantation.
Cancelas JA; Hernández-Jodra M; Zamora C; Perez-Oteyza J; Brieva JA; Roldan E; Navas G; Garcia-Laraña J; Lopez J; Odriozola J
Vox Sang; 1994; 67(4):362-7. PubMed ID: 7535498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]